NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA

This announcement is not an offer to sell, or a solicitation of an offer to acquire any securities. This announcement is an advertisement and not a prospectus and investors should not purchase any securities referred to in this announcement except on the basis of information in the prospectus to be published by Cardio3 BioSciences SA in due course in connection with the offering and admission to listing of its shares on NYSE Euronext Brussels and NYSE Euronext Paris.

Cardio3 BioSciences Announces Intention to Launch an Initial Public Offering[i] on NYSE Euronext Brussels and NYSE Euronext Paris

Mont-Saint-Guibert, Belgium, June 4th, 2013 - The biotechnology company, Cardio3 BioSciences SA (Cardio3 BioSciences), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces it is considering to raise new funds through an Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris.

Cardio3 BioSciences' lead product is C-Cure®, a unique therapy that involves taking cells from a patient's bone marrow. Through a proprietary process called cardiopoiesis, the cells are re-programmed so that they become heart precursor cells with the aim of replicating the normal process of cardiac development in the embryo and healing the failing heart. The cells, known as cardiopoietic cells, are then injected back into the patient's heart through a minimally invasive procedure using a proprietary catheter called C-Cath$_{ez}$®, with the goal of repairing damaged tissue and improving heart function, clinical outcomes and quality of life.

Cardio3 BioSciences is developing C-Cure® for the treatment of heart failure, one of the world's greatest unmet medical needs. A person living to age 40 years has a one in five risk of developing heart failure and, once the disorder is apparent, a one in three chance of dying within a year of diagnosis *(McMurray and Pfeffer 2005 - see below)*. US$32 billion per annum is spent on heart failure patients in the US alone *(Go et al. 2013 - see below)*.

C-Cure® builds on research conducted at Mayo Clinic (Rochester, Minnesota, USA), Cardio3 BioSciences and Cardiovascular Centre Aalst (Aalst, Belgium). The product is currently being tested in Europe in a Phase III trial (CHART-1 - Congestive Heart failure Cardiopoietic Regenerative Therapy). CHART-1 is the world's first phase III trial using pre-programmed cardiac progenitor cells for the treatment of heart failure.

The CHART-1 study builds on the successful results of Cardio3 BioSciences' Phase II trial of C-Cure, which were recently published in the Journal of the American College of Cardiology (JACC) *(Bartunek et al. 2013 - see below)*. The study showed an increase of 25% of the Left Ventricular Ejection Fraction (LVEF) which was statistically significant ($p<0.0001$), as was the increase in exercise capacity measured by the 6 minutes Walking Distance test (+77m change at 6months versus baseline in

[i] Should the Company decide to launch the Initial Public Offering described in this document, the Prospectus approved by the FSMA (the Authority responsible for this transaction), will be made available on the Company's website (www.c3bs.com)

comparison to the control group (p<0.01). An accompanying editorial in JACC *(Murry et al. 2013 - see below)* commented that "*Six months after treatment, the cell therapy group had a 7 percent absolute improvement in EF (ejection fraction) over baseline, versus a non-significant change in the control group. This improvement in EF is dramatic, particularly given the duration between the ischemic injury and cell therapy. It compares favourably with our most potent therapies in heart failure.*"

Cardio3 BioSciences intends to start a trial in the USA (the CHART-2 trial) when and if the FDA authorizes its start. The CHART programme is designed as two pivotal studies to obtain marketing authorisation in Europe and in the USA respectively, either alone, or in combination with other clinical trials.

In addition to C-Cure®, Cardio3 BioSciences has developed a proprietary technology aimed at maximising the delivery efficiency of therapeutics into the heart muscle. C-Cath$_{ez}$® is an intra-myocardial delivery catheter, designed to enhance myocardial therapeutic agents' retention. The Company has obtained CE marking in April 2012 from NSAI (an Irish Notified Body).

Cardio3 BioSciences also has early stage programs in progress aimed at using protein therapeutics to treat acute myocardial infarction (AMI) or "heart attack". The IPO is expected to consist of an offering of new shares which will be listed on NYSE Euronext Brussels and NYSE Euronext Paris. Kempen & Co has been appointed as Sole Global Coordinator and Kempen & Co and Invest Securities have been appointed as Joint Bookrunners.

***** END *****

For more information contact:

Cardio3 BioSciences — www.c3bs.com
Dr Christian Homsy, CEO — Tel : +32 10 39 41 00
Anne Portzenheim, Communication Manager — aportzenheim@c3bs.com

Citigate Dewe Rogerson — Tel : +44 (0) 207 638 9571
David Dible/Chris Gardner/Malcolm Robertson — david.dible@citigatedr.co.uk

of listing on NYSE Euronext Brussels and NYSE Euronext Paris may be influenced by things such as market conditions. There is no guarantee that such listing will occur and you should not base your financial decisions on Cardio3 BioSciences' intentions in relation to such listing at this stage. Acquiring investments to which this announcement relates may expose an investor to a significant risk of losing the entire amount invested. Persons considering such investments should consult an authorised person specialising in advising on such investments. This announcement does not constitute a recommendation concerning the contemplated offering. The value of the shares can decrease as well as increase. Potential investors should consult a professional advisor as to the suitability of the contemplated offering for the person concerned.

This announcement is not an offer of securities in the United States. The securities to which these materials relate have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. There will be no public offering of the securities in the United States.

The Company has not authorized any offer to the public of securities in any Member State of the European Economic Area other than Belgium and France. With respect to each Member State of the European Economic Area other than Belgium and France and which has implemented the Prospectus Directive (each, a "Relevant Member State"), no action has been undertaken or will be undertaken to make an offer to the public of securities requiring a publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in a Relevant Member State to qualified investors in that Relevant Member State within the meaning of the Prospectus Directive.

For the purposes of this paragraph, the expression an "offer to the public of securities" in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase any securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State and the expression "Prospectus Directive" means Directive 2003/71/EC (as amended) and includes any relevant implementing measure in each Relevant Member State.

This announcement is being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i), (ii) and (iii) above together being referred to as "relevant persons"). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

About Cardio3 BioSciences

Cardio3 BioSciences is a leading Belgian biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The

company was founded in 2007. Cardio3 BioSciences leverages research collaborations in the US and in Europe with, amongst other, Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new cardiac progenitor cells that behave like those cells lost to heart disease. This reprogramming process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath®$_{ez}$, a technologically advanced injection catheter with superior efficiency of delivery of biotherapeutic agents into the myocardium.

In accordance with the Bayh-Dole Act, Mayo Clinic has licensed the technology underlying C-Cure to Cardio3 BioSciences and received an equity position in the company in the context of the license. Mayo Clinic and the inventors of the technology, Drs. Andre Terzic and Atta Behfar, have a financial interest associated with the technology related to this research. While no royalties have accrued to date, Mayo Clinic has rights to receive future royalties which will be shared with Drs. Terzic and Behfar in accordance with the Mayo Clinic Royalty sharing policy.

Bartunek, J., A. Behfar, D. Dolatabadi, M. Vanderheyden, M. Ostojic, J. Dens, B. E. Nakadi, M. Banovic, B. Beleslin, M. Vrolix, V. Legrand, C. Vrints, J. L. Vanoverschelde, R. Crespo-Diaz, C. Homsy, M. Tendera, S. Waldman, W. Wijns and A. Terzic (2013). "Cardiopoietic stem cell therapy in heart failure The C-CURE multicenter randomized trial with lineage-specified biologics." J Am Coll Cardiol.

Go, A. S., D. Mozaffarian, V. r. L. Roger, E. J. Benjamin, J. D. Berry, W. B. Borden, D. M. Bravata, S. Dai, E. S. Ford, C. S. Fox, S. Franco, H. J. Fullerton, C. Gillespie, S. M. Hailpern, J. A. Heit, V. J. Howard, M. D. Huffman, B. M. Kissela, S. J. Kittner, D. T. Lackland, J. H. Lichtman, L. D. Lisabeth, D. Magid, G. M. Marcus, A. Marelli, D. B. Matchar, D. K. McGuire, E. R. Mohler, C. S. Moy, M. E. Mussolino, G. Nichol, N. P. Paynter, P. J. Schreiner, P. D. Sorlie, J. Stein, T. N. Turan, S. S. Virani, N. D. Wong, D. Woo and M. B. Turner (2013). "Heart Disease and Stroke Statistics" 2013 Update: A Report From the American Heart Association." Circulation **127**(1): e6-e245.

McMurray, J. J. and M. A. Pfeffer (2005). "Heart failure." Lancet **365**(9474): 1877-89.

Murry, C. E., N. J. Palpant and W. R. Maclellan (2013). "Cardiopoietry in Motion: Primed Mesenchymal Stem Cells for Ischemic Cardiomyopathy." J Am Coll Cardiol.